Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 11 systematic review(s)/meta-analysis(es). ^[1-11]
• In procedural sedation for older patients, remimazolam demonstrated no significant differences in sedation success, dizziness, postoperative nausea and vomiting, or recovery time when compared to other sedatives.
• During gastroscope sedation, remimazolam significantly reduced the incidence of respiratory depression, hypoxemia, bradycardia, dizziness, injection site pain, and hypotension compared to propofol.
• When combined with flumazenil, remimazolam shortened emergence time, extubation time, and post-anesthesia care unit (PACU) stay compared to propofol, while also reducing the incidence of respiratory depression.
• For gastrointestinal endoscopy, remimazolam showed higher procedural success and a lower need for rescue medication, along with a reduced incidence of hypotension and adverse events compared to midazolam.
• Remimazolam was associated with a lower incidence of hypotension, bradycardia, respiratory depression, and injection pain compared to propofol across various sedation settings.
• When used with flumazenil, remimazolam reduced the incidence of respiratory depression but increased the risk of re-sedation compared to propofol.
• Hypotension and bradycardia were the most commonly reported adverse events, with rare cases of cardiac arrest observed.